CClinicalTrials.gg
CompletedNCT03986931Updated Jan 22, 2025Results posted

A Pharmacist Intervention for Monitoring and Treating Hypertension Using Bidirectional Texting

An interventional study of Experimental: Pharmacist-Bidirectional Texting Group and Active Comparator: Control Group in Hypertension, sponsored by Linnea Polgreen. Completed at 1 site in United States. Open to participants aged 21 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by Linnea Polgreen · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
535
Allocation
Randomized
Ages
21 Years to 100 Years
Sex
All
01

Study summary

Bidirectional texting is an effective way to collect home blood pressure (BP) measurements from subjects, but collecting BP measurements and sending them to physicians does not necessarily lead to decreased BP. Pharmacist interventions have been successful in decreasing subject BP. However, pharmacists are expensive, and in successful interventions, spent a substantial amount of time collecting home BP measurements. In this study, a proven pharmacist intervention will be added to a bidirectional texting program to determine if a combined pharmacist-bidirectional texting intervention is successful at decreasing subject BP and increasing subject BP treatment intensification in a cost-effective manner. This study will be a cluster-randomized, controlled trial of a new intervention.

Read the detailed description

HTN is associated with the greatest attributable risk for mortality among all modifiable risk factors for cardiovascular disease.[1] In 2014, there were approximately 72 million adults (29%) with HTN in the US.[2] Several clinical trials have demonstrated that antihypertensive medications reduce cardiovascular events.[3] For example, even a 5 mm Hg difference in systolic BP (SBP) over 3-5 years can reduce the risk of cardiovascular complications and strokes by 25-30%.[4] Yet, approximately 20% of U.S. adults are unaware of their HTN,[5] and among patients diagnosed with HTN, 47% are uncontrolled.[2] Thus, there is a critical need to effectively treat patients with HTN.

Clinical inertia has been identified as the primary cause for delays in achieving BP control for over 20 years.[6-8] Providers often discount office BP readings that may be falsely elevated due to observer or measurement error and/or the clinical surroundings (e.g., white coat HTN).[9-11] Patients are often seen only once or twice a year which further delays BP control. Furthermore,[8, 12] BP goals are achieved in only 49% of the patients who take anti-hypertensive medications.[5] New approaches for acquiring more BP readings are also needed to better monitor and titrate treatment because a significant proportion of patients on therapy are not adequately controlled despite frequent physician visits.

Home BP measurements, (i.e., having patients take their BP at home), can facilitate the more timely diagnosis of HTN by reducing diagnostic uncertainty. In fact, home measurements are better prognostic indicators of stroke and cardiovascular mortality than clinic measurements,[13-15] are more closely correlated with end-organ damage from HTN than clinic measurements,[16, 17] are cost effective and well-tolerated by patients,[18] and generate BP readings that are at least as reproducible as clinic readings.[19] Home BP measurements, if available, may help physicians overcome barriers related to clinical inertia.[20] However, the data must be followed by action. The researchers have pioneered physician-pharmacist collaborative management (PPCM) that has been shown to decrease clinical inertia and improve BP control.[21, 22] Pharmacists have been embedded within the medical office to perform BP management. The pharmacists are able to assess patients' needs and provide recommendations to physicians regarding treatment changes, providing patients with timely therapy adjustments.[23] However, many medical office leaders are unable to hire clinical pharmacists due to limited resources. Therefore, a "virtual", remote clinical pharmacy service has been developed.[24] Pharmacists were able to obtain electronic medical record (EMR) access at all intervention offices for private physician offices throughout Iowa. While the physicians accepted 95% of the pharmacists' recommendations, the effect on improving BP was modest (manuscript under review). Adding the proposed texting platform with home BP monitoring should markedly improve the potency of our remote, telepharmacy intervention.

This trial exhibits clinical equipoise because, although it is known that texting is an efficient method for obtaining home BP measurements, and that pharmacist interventions to improve BP are cost-effective, it is not known if combining these two interventions will also be cost effective. There are four reasons why this study might not be successful. First, while meta-analyses have found significantly improved BP with pharmacist interventions some studies were not successful.[25] Second, more data does not necessarily mean better data: patients could report false values, BP could be abnormally low or high during the measurement period, or the data could be ignored. Third, even better data might not lead to better outcomes: data could be ignored by pharmacists, physicians or patients; pharmacists' recommendations could be ignored by physicians or patients. Fourth, even if the study is effective at improving subject outcomes, it might not be cost effective. Texting might not save as much time as hypothesized. Thus, further research is needed to address these gaps in knowledge.

There is a critical need for an easy-to-use, cost-effective, mobile health (m-health) approach to assist patients and healthcare providers with screening, diagnosis, and monitoring of HTN. Small medical offices and those located in poor or rural areas are unable to operationalize team-based care with pharmacists. The researchers have overcome this barrier with the use of a remote clinical pharmacy services. Coronary heart disease deaths could be reduced by 15-20% and stroke deaths by 20-30% if this intervention effectively improves BP and is implemented more widely in primary care offices.

The goal of this proposal is to evaluate whether a scalable, short messaging service (SMS) approach combined with a pharmacist-based intervention improves BP management cost effectively. To achieve this objective, the following specific aims are proposed:

  1. Determine if mean BP 12 months after the intervention decreases more for the intervention group than the control group. The working hypothesis is that those in the pharmacist-intervention group will achieve larger BP decreases than those in the control group.
  2. Determine if the intervention leads to more intensification of therapy than in the control group. The working hypothesis is that subjects in the pharmacist-intervention group will have more treatment changes than those in the control group.
  3. Determine the cost effectiveness of the intervention. The working hypothesis is that the intervention will be cost effective when compared to the control group.
02

Conditions studied

  • Hypertension

Browse trials for

03

Who can participate

Ages eligible
21 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Fluent in English or Spanish
  • Have a clinic measured blood pressure of > or = 145 mmHg and/or > or = 95 mmHg at two previous clinic visits or one previous clinic visit and on the day of enrollment
  • Must be a patient at Family Medicine, River Crossings, Scott Blvd, or Muscatine University of Iowa Clinics
  • Live in a zip code that is scored as a 4-10 on the Rural-Urban Commuting Area codes

Exclusion criteria

Exclusion Criteria:

  • Currently pregnant or planning to become pregnant in the next year
  • Upper arm circumference greater than 50 cm (20 in)
  • Prisoner status
  • Unable to provide own informed consent
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
535 participants (actual)

Study arms

  • Experimental
    Pharmacist-Bidirectional Texting Group

    Patients enrolled in the Pharmacist-Bidirectional Texting Group will return 7 morning and 7 evening blood pressure measurements via text message. The report will be shared with a pharmacist who will monitor them for 12 months. The pharmacist will have access to their entire medical record and will provide support and education via text messaging, email, or phone calls, whichever is preferred by the patient. The pharmacist will develop a care plan and make recommendations to the physician through the electronic medical record to quickly adjust therapy to improve control. They will also recommend laboratory testing if indicated. They will have contact with the patient every 2-3 weeks while blood pressure is uncontrolled, and at least every 2 months when it is controlled. The pharmacist will track all recommendations made to physicians and whether or not they were implemented, modified, or rejected.

    Other: Experimental: Pharmacist-Bidirectional Texting Group

  • Active comparator
    Control Group

    Patients randomized to the control group will also return 7 morning and 7 evening blood pressure measurements. The report will be shared with a pharmacist who will call the patient to discuss the measurements and possibly recommend follow up with a physician, but no other pharmacist intervention or monitoring will occur during the 12 months.

    Other: Active Comparator: Control Group

Interventions

  • OtherExperimental: Pharmacist-Bidirectional Texting Group

    The goal of this intervention is to determine if bidirectional texting and pharmacist monitoring will improve blood pressure control.

  • OtherActive Comparator: Control Group

    This group will receive bidirectional texting, but no pharmacist monitoring.

05

What researchers measure

Primary outcomes

  1. Difference in Change in Systolic Blood Pressure- 12 Months

    The difference between the groups in the change from baseline to 12 months in systolic blood pressure in mm Hg.

    Time frame: 12 months

Secondary outcomes

  1. Difference in Change in Diastolic Blood Pressure- 12 Months

    The difference between the groups in the change from baseline to 12 months in diastolic blood pressure in mmHg.

    Time frame: 12 months

  2. Number of Medication Changes From 6 to 12 Months

    Total number of medication changes (i.e., dose, discontinuation, initiation, etc.) from 6 months to 12 months as documented in the medical record.

    Time frame: 12 months

  3. Dollars Spent Per Patient for 12 Month Bidirectional Texting/Pharmacist Intervention

    Total cost of medications, time spent by research staff, and clinics visits per patient from baseline.

    Time frame: 12 months

06

Results

Posted Jan 22, 2025

Participant flow

Participant flow — Overall Study
MilestonePharmacist-Bidirectional Texting GroupControl Group
Started209211
Completed209211
Not completed00

Outcome measures

PrimaryDifference in Change in Systolic Blood Pressure- 12 Months

The difference between the groups in the change from baseline to 12 months in systolic blood pressure in mm Hg.

Time frame:
12 months
Reported as:
Mean · mmHg
Difference in Change in Systolic Blood Pressure- 12 Months
mmHgPharmacist-Bidirectional Texting GroupControl Group
Difference in Change in Systolic Blood Pressure- 12 Months-23.8 ± 19.4-19.6 ± 19.4
SecondaryDifference in Change in Diastolic Blood Pressure- 12 Months

The difference between the groups in the change from baseline to 12 months in diastolic blood pressure in mmHg.

Time frame:
12 months
Reported as:
Mean · mmHg
Difference in Change in Diastolic Blood Pressure- 12 Months
mmHgPharmacist-Bidirectional Texting GroupControl Group
Difference in Change in Diastolic Blood Pressure- 12 Months-9.1 ± 13.4-9.6 ± 11.4
SecondaryNumber of Medication Changes From 6 to 12 Months

Total number of medication changes (i.e., dose, discontinuation, initiation, etc.) from 6 months to 12 months as documented in the medical record.

Time frame:
12 months
Reported as:
Mean · Medication Changes
Number of Medication Changes From 6 to 12 Months
Medication ChangesPharmacist-Bidirectional Texting GroupControl Group
Number of Medication Changes From 6 to 12 Months0.59 ± 0.980.44 ± 0.84
SecondaryDollars Spent Per Patient for 12 Month Bidirectional Texting/Pharmacist Intervention

Total cost of medications, time spent by research staff, and clinics visits per patient from baseline.

Time frame:
12 months
Reported as:
Mean · Dollars
Dollars Spent Per Patient for 12 Month Bidirectional Texting/Pharmacist Intervention
DollarsPharmacist-Bidirectional Texting GroupControl Group
Dollars Spent Per Patient for 12 Month Bidirectional Texting/Pharmacist Intervention980.17 ± 1127.91838.95 ± 713.45

Adverse events

Collected over 12 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pharmacist-Bidirectional Texting Group7/209 (3.3%)0/209 (0%)0/209 (0%)
Control Group4/211 (1.9%)0/211 (0%)0/211 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pharmacist-Bidirectional Texting GroupControl GroupTotal
Mean58.7 ± 13.758.4 ± 13.658.6 ± 13.6
Sex: Female, Male
Sex: Female, Male(Participants)Pharmacist-Bidirectional Texting GroupControl GroupTotal
Female96113209
Male11398211
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pharmacist-Bidirectional Texting GroupControl GroupTotal
Hispanic or Latino494897
Not Hispanic or Latino160162322
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pharmacist-Bidirectional Texting GroupControl GroupTotal
American Indian or Alaska Native112
Asian303
Native Hawaiian or Other Pacific Islander000
Black or African American11516
White184196380
More than one race303
Unknown or Not Reported7916
Body Mass Index
Body Mass Index(kg/m^2)Pharmacist-Bidirectional Texting GroupControl GroupTotal
Mean32.6 ± 7.433.7 ± 7.833.1 ± 7.7
Level of Education
Level of Education(Participants)Pharmacist-Bidirectional Texting GroupControl GroupTotal
< High School324678
High School6656122
Some College374683
Associate's Degree272047
Bachelor's Degree302454
Master's Degree101020
Doctoral Degree5611
Trade School235
Smoking History
Smoking History(Participants)Pharmacist-Bidirectional Texting GroupControl GroupTotal
Never Smoked117120237
Current Smoker373471
Former Smoker5557112
Baseline Systolic Blood Pressure
Baseline Systolic Blood Pressure(mmHg)Pharmacist-Bidirectional Texting GroupControl GroupTotal
Mean156.0 ± 13.7153.4 ± 14.0154.3 ± 14.0

5 further baseline measures are reported on the registry.

07

Study locations

1 site
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
08

References and documents

Publications

  • Palmer MJ, Machiyama K, Woodd S, Gubijev A, Barnard S, Russell S, Perel P, Free C. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults. Cochrane Database Syst Rev. 2021 Mar 26;3(3):CD012675. doi: 10.1002/14651858.CD012675.pub3. PubMed 33769555 ↗
  • Polgreen LA, Carter BL, Polgreen PM, Snyder PM, Sewell DK, Bayman EO, Francis SL, Simmering JE, Parker C, Finkelstein R. A pharmacist intervention for monitoring and treating hypertension using bidirectional texting: PharmText BP. Contemp Clin Trials. 2020 Nov;98:106169. doi: 10.1016/j.cct.2020.106169. Epub 2020 Oct 7. PubMed 33038500 ↗

Study documents

  • Protocol and statistical analysis plan · Sep 21, 2020
  • Informed consent form · Aug 20, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT03986931
Lead sponsor
Linnea Polgreen
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Responsible party
Linnea Polgreen (Associate Professor, Department of Pharmacy Practice and Science / Division of Health Services Research, University of Iowa) — Sponsor-investigator
First posted
Jun 14, 2019
Start date
Feb 25, 2020
Primary completion
Jun 22, 2023
Completion
Jun 22, 2023
Results posted
Jan 22, 2025
Last update
Jan 22, 2025

Study contacts

Linnea A Polgreen, PhD
principal investigator · University of Iowa

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion